Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 3.205
-0.210 (-6.15%)
Oct 13, 2026, 4:25 PM CET
Nykode Therapeutics AS Ratios and Metrics
Market cap in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,047 | 788 | 995 | 6,988 | 8,287 | 23,372 | |
Market Cap Growth | 51.90% | -20.81% | -85.77% | -15.67% | -64.54% | 9.44% |
Enterprise Value | 621 | 178 | -270 | 5,353 | 6,040 | 21,724 |
Last Close Price | 3.42 | 2.41 | 1.99 | 13.98 | 18.37 | 52.72 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 24.28 | 24.28 | 24.28 | 23.99 | 4.32 |
PS Ratio | 242.62 | 172.48 | 9.56 | 51.73 | 93.16 | 74.18 |
PB Ratio | 1.40 | 0.85 | 0.64 | 4.02 | 5.36 | 13.67 |
P/TBV Ratio | 1.40 | 0.85 | 0.64 | 4.03 | 5.36 | 13.67 |
P/FCF Ratio | - | - | - | - | - | 9341.31 |
P/OCF Ratio | - | - | - | - | - | 2296.91 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 149.93 | 38.99 | - | 39.62 | 67.90 | 68.94 |
EV/FCF Ratio | - | - | - | - | - | 8682.61 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
Debt / FCF Ratio | - | - | - | - | - | 25.25 |
Net Debt / Equity Ratio | -0.53 | -0.63 | -0.82 | -0.92 | -1.28 | -1.14 |
Net Debt / EBITDA Ratio | 1.60 | 2.07 | 2.35 | 2.73 | 3.81 | 20.70 |
Net Debt / FCF Ratio | 1.58 | 1.96 | 2.18 | 1.59 | 8.60 | -778.98 |
Asset Turnover | 0.01 | 0.00 | 0.05 | 0.06 | 0.04 | 0.14 |
Quick Ratio | 11.52 | 9.88 | 12.78 | 7.94 | 5.41 | 8.12 |
Current Ratio | 11.52 | 9.99 | 12.87 | 8.04 | 5.44 | 8.16 |
Return on Equity (ROE) | -25.06% | -10.75% | -25.25% | -21.42% | -24.35% | -5.05% |
Return on Assets (ROA) | -17.48% | -14.10% | -16.70% | -16.90% | -13.64% | -2.72% |
Return on Invested Capital (ROIC) | -72.81% | -98.49% | -250.18% | - | - | - |
Return on Capital Employed (ROCE) | -33.70% | -30.50% | -33.50% | -31.00% | -29.10% | -4.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -20.39% | -15.67% | -44.34% | -5.10% | -5.08% | -0.36% |
FCF Yield | -24.11% | -37.75% | -58.58% | -14.30% | -2.78% | 0.01% |
Dividend Yield | 31.20% | - | 32.83% | - | - | - |
Buyback Yield / Dilution | - | - | -8.66% | -3.58% | -1.32% | 3.31% |
Total Shareholder Return | 29.28% | - | 24.17% | -3.58% | -1.32% | 3.31% |